



Library and Information Service  
Royal College of Psychiatrists  
17 Belgrave Square  
London SW1X 8PG  
☎ 0171-235-2351-X138

## EDITORIALS

### 193 Original publications

A. Kerr

### 194 Research and development in the NHS. New lamps for old

A. Burns and S. Lewis

### 197 Qualitative research

K. Bustin, W. Parry-Jones, M. Livingston, A. Bogan and S. Wood

## REVIEW ARTICLES

### 200 Asperger syndrome and high-functioning autism

C. Gillberg

### 210 Questionable validity of 'dissociative amnesia' in trauma victims. Evidence from prospective studies

H. G. Pope, Jr, J. I. Hudson, J. A. Bodkin and P. Oliva

### 216 Commentary: Questionable validity of 'dissociative amnesia' in trauma victims

C. R. Brewin

## PAPERS

### 218 Mental disorder and violence. A special (high security) hospital study

P. J. Taylor, M. Leese, D. Williams, M. Butwell, R. Daly and E. Larkin

### 227 Meta-analysis of trials comparing antidepressants with active placebos

J. Moncrieff, S. Wessely and R. Hardy

### 232 Commentary: Meta-analysis of trials comparing antidepressants with active placebos

D. Healy

### 235 Epilepsy and non-organic non-affective psychosis. National epidemiologic study

S. R. Bredkjær, P. B. Mortensen and J. Parnas

### 239 Thirteen-year follow-up of deliberate self-harm, using linked data

D. Hall, F. O'Brien, C. Stark, A. Pelosi and H. Smith

### 243 Reduced latent inhibition in people with schizophrenia: an effect of psychosis or of its treatment

J. H. Williams, N. A. Wellman, D. P. Geaney, P. J. Cowen, J. Feldon and J. N. P. Rawlins

### 250 Psychiatric disorders as a factor in sick-leave due to other diagnoses. A general population-based study

G. Hensing and F. Spak

### 257 Postal self-exposure treatment of recurrent nightmares. Randomised controlled trial

M. Burgess, M. Gill and I. Marks

### 263 Validity of childhood disintegrative psychosis. General findings of a long-term follow-up study

S. E. Mouridsen, B. Rich and T. Isager

### 268 Multivariate genetic analysis of the causes of temperance board registrations. In all Swedish male-male twin pairs born 1926-1949

K. S. Kendler, L. M. Karkowski, C. A. Prescott, M. C. Neale and N. L. Pedersen

## PRELIMINARY REPORT

### 273 Adults with Williams syndrome. Preliminary study of social, emotional and behavioural difficulties

M. Davies, O. Udwin and P. Howlin

## COLUMNS


277 Correspondence

280 One hundred years ago

281 Book reviews

288 Contents of *The American Journal  
of Psychiatry*


# Debbie doesn't know that Cipramil is now indicated for panic disorder



... she just knows her doctor  
made a logical choice

As a patient with Panic Disorder, Debbie is beginning to appreciate the value of the Cipramil treatment that her doctor has newly prescribed.

Of course, Debbie would no more talk of the recently extended indication for Cipramil than its high selectivity<sup>1,2</sup>, good tolerability<sup>3</sup>, and low risk of drug interactions<sup>4,5</sup>. She just recognises the difference that Cipramil makes to the stability and quality of her life.



**Cipramil**<sup>▼</sup>  
citalopram

now indicated for panic disorder

**Presentation:** 'Cipramil' tablets 10 mg; PL 0458/0057, each containing 10 mg of citalopram as the hydrobromide. 28 (OP) 10 mg tablets £12.77. 'Cipramil' tablets 20 mg; PL 0458/0058, each containing 20 mg of citalopram as the hydrobromide. 28 (OP) 20 mg tablets £21.28. **Indications:** Treatment of depressive illness in the initial phase and as maintenance against relapse/recurrence. Treatment of panic disorder, with or without agoraphobia. **Dosage:** *Treating depression:* **Adults:** 20 mg a day. Depending upon individual patient response, this may be increased in 20 mg increments to a maximum of 60 mg. Tablets should not be chewed, and should be taken as a single oral daily dose, in the morning or evening without regard for food. Treatment for at least 6 months is usually necessary to provide adequate maintenance against the potential for relapse. *Treating panic disorder:* 10 mg daily for the first week, increasing to 20 mg daily. Depending upon individual patient response, dosage may be further increased to a maximum of 60 mg daily. Depending upon individual patient response, it may be necessary to continue treatment for several months. **Elderly:** 20 mg a day increasing to a maximum of 40 mg dependent upon individual patient response. **Children:** Not recommended. **Reduced hepatic/renal function:** Restrict dosage to lower end of range in hepatic impairment. Dosage adjustment not necessary in cases of mild/moderate renal impairment. No information available in severe renal impairment (creatinine clearance <20ml/min). **Contra-Indications:** Combined use of 5-HT agonists. Hypersensitivity to citalopram. **Pregnancy and Lactation:** Safety during human pregnancy and lactation has not been established. Use only if potential benefit outweighs possible risk. **Precautions:** Driving and operating machinery. History of mania. Caution in patients at risk of

cardiac arrhythmias. Do not use with or within 14 days of MAO inhibitors: leave a seven day gap before starting MAO inhibitor treatment. Use a low starting dose for panic disorder, to reduce the likelihood of an initial anxiogenic effect (experienced by some patients) when starting pharmacotherapy. **Drug Interactions:** MAO inhibitors (see Precautions). Use lithium and tryptophan with caution. Routine monitoring of lithium levels need not be adjusted. **Adverse Events:** Most commonly nausea, sweating, tremor, somnolence and dry mouth. With citalopram, adverse effects are in general mild and transient. When they occur, they are most prominent during the first two weeks of treatment and usually attenuate as the depressive state improves. **Overdosage:** Symptoms have included somnolence, coma, sinus tachycardia occasional nodal rhythm, episode of grand mal convulsion, nausea, vomiting, sweating and hyperventilation. No specific antidote. Treatment is symptomatic and supportive. Early gastric lavage suggested. **Legal Category:** POM 24.1.95. Further information available upon request. Product licence holder: Lundbeck Ltd., Sunningdale House, Caldecotte Lake Business Park, Caldecotte, Milton Keynes, MK7 8LF. © 'Cipramil' is a Registered Trade Mark. © 1997 Lundbeck Ltd. Data of preparation: April 1997. 0897/CIP/501/044

1. Hyttel J. XXII Nordiske Psykiater Kongres, Reykjavik, 11 August 1988:11-21. 2. Eison AS et al Psychopharmacology Bul 1990; 26 (3): 311-315. 3. Wade AG et al. Br J Psychiatry 1997; 170: 549-553. 4. Sindrup SH et al. Ther Drug Monit 1993; 15 11-17. 5. Van Harten J. Clin Pharmacokinetics 1993; 24: 203-20. 6. Jeppesen U et al. Eur J Clin Pharmacol 1996; 51: 73-78.



**EDITOR** Greg Wilkinson LIVERPOOL

## EDITORIAL BOARD

### DEPUTY EDITOR

Alan Kerr  
NEWCASTLE UPON TYNE

### ASSOCIATE EDITORS

Sidney Crown  
LONDON

Julian Leff  
LONDON

Sir Martin Roth, FRS  
CAMBRIDGE

Sir Michael Rutter, FRS  
LONDON

Peter Tyrer  
LONDON

### EDITORIAL ADVISERS

Tony Johnson  
CAMBRIDGE

Kathleen Jones  
YORK

Martin Knapp  
LONDON

Herschel Prins  
LEICESTER

Sir John Wood  
SHEFFIELD

### ASSISTANT EDITORS

Louis Appleby  
MANCHESTER

Alistair Burns  
MANCHESTER

Patricia Casey  
DUBLIN

John Cookson  
LONDON

Tom Fahy  
LONDON

Anne Farmer  
CARDIFF

Michael Farrell  
LONDON

Nicol Ferrier  
NEWCASTLE UPON TYNE

Richard Harrington  
MANCHESTER

Sheila Hollins  
LONDON

Jeremy Holmes  
BARNSTAPLE

Michael King  
LONDON

Michael Kopelman  
LONDON

Alan Lee  
FLOTTINGHAM

Glyn Lewis  
CARDIFF

Shôn Lewis  
MANCHESTER

Robin McCreadie  
DUMFRIES

Ian McKeith  
NEWCASTLE UPON TYNE

J. Spencer Madden  
UPTON-BY-CHESTER

David Owens  
LEEDS

Ian Pullen  
MELROSE

Henry Rollin  
LONDON

Jan Scott  
NEWCASTLE UPON TYNE

Andrew Sims  
LEEDS

George Stein  
LONDON

### CORRESPONDING EDITORS

Andrew Cheng  
TAIWAN

Kenneth Kendler  
USA

Arthur Kleinman  
USA

Paul Mullen  
AUSTRALIA

Michele Tansella  
ITALY

J. L. Vázquez-Barquero  
SPAIN

### STATISTICAL ADVISER

Pak Sham  
LONDON

### STAFF

PUBLICATIONS MANAGER  
Dave Jago

DEPUTY MANAGER  
Helen Bolton

SCIENTIFIC EDITOR  
Andrew Morris

ASSISTANT SCIENTIFIC EDITORS  
Lucretia King  
Zoë Stagg

EDITORIAL ASSISTANTS  
Zofia Ashmore

Julia Burnside  
Rachel Gold

MARKETING ASSISTANT  
Dominic Bentham

## Subscriptions

Non-members of the College should contact the Publications Subscription Department, Royal Society of Medicine Press Limited, PO Box 9002, London W1A 0ZA (tel. 0171 290 2928; fax 0171 290 2929). Annual subscription rates for 1998 (12 issues post free) are as follows:

	INSTITUTIONS	INDIVIDUALS
Europe (& UK)	£172	£150
US	\$350	\$258
Elsewhere	£205	£162

Full airmail is £36/  
US\$64 extra

Single copies of the  
journal are £14, \$25  
(post free)

Queries from non-members about missing or faulty copies should be addressed within six months to the same address; similar queries from College members should be addressed to the Registration Subscription Department, The Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG.

Payment should be made out to the British Journal of Psychiatry.

## Back issues

Back issues published before 1996 may be purchased from William Dawson & Sons Ltd, Cannon House, Folkestone, Kent (tel. 01303 850 101).

## Advertising

Correspondence and copy should be addressed to Peter T. Mell, Advertising Manager, PTM Publishers Ltd, 282 High Street, Sutton, Surrey SM1 1PQ (tel. 0181 642 0162, fax 0181 643 2275).

## US Mailing Information

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists. Subscription price is \$350. Second class postage paid at Rathway, NJ. Postmaster send address corrections to the British Journal of Psychiatry, c/o Mercury Airfreight International Ltd Inc., 2323 Randolph Avenue, Avenel, New Jersey 07001.

The paper used in this publication meets the minimum requirements of the American National Standard for Information Sciences - Permanence of Paper for Printed Library Materials. ANSI Z39.48-1984

Typeset by Dobbie Typesetting Ltd, Tavistock

Printed by Henry Ling Ltd, The Dorset Press, 23 High East Street, Dorchester, Dorset DT1 1HD.

## Past Editors

Eliot Slater	1961-72	John L. Crammer	1978-83
Edward H. Hare	1973-77	Hugh L. Freeman	1984-93

Founded by J. C. Bucknill in 1853 as the *Asylum Journal* and known as the *Journal of Mental Science* from 1858 to 1963

© 1998 The Royal College of Psychiatrists. Unless so stated, material in the *British Journal of Psychiatry* does not necessarily reflect the views of the Editor or the Royal College of Psychiatrists. The publishers are not responsible for any error of omission or fact.

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists (a registered charity, registration number 228636). The *BJP* publishes original work in all fields of psychiatry. Manuscripts for publication should be sent to the Editor, *British Journal of Psychiatry*, 17 Belgrave Square, London SW1X 8PG. Queries, letters to the Editor and book reviews may also be sent electronically to [zashmore@tsave.rcpsych.ac.uk](mailto:zashmore@tsave.rcpsych.ac.uk).

## Instructions to authors

Full instructions to authors are given at the beginning of the January and July issues, and on the Web Site below. Copies are also available from the Journal Office.



## CONSULTANTS



Choose your quality locum positions now!!!

Short or long term  
Competitive rates  
All areas of the U.K.  
Excellent 'on call' posts  
1:7 or better

Documentation/visas arranged

Permanent positions also available

Call **DIRECT MEDICAL APPOINTMENTS**


THE CONSULTANTS CHOICE

for a professional and prompt service

Tel: +44 (0)1792 472525

Fax: +44 (0)1792 472535

Email: [medical.appointments@cyberstop.net](mailto:medical.appointments@cyberstop.net)



LONDON : DUBLIN

MRCPsych PART I

Intensive exam-oriented weekend courses

- Covering: Theory for *new syllabus*  
Technique & tactics  
Over 2000 relevant MCQs  
Practice MCQ exams


London: 7, 8 & 14, 15 March 1998 (4 days)

Dublin: 21, 22 March 1998 (2 days)

The Secretary  
NB Medical Education  
PO Box 767  
Oxford  
OX1 1XD

- Full details: 01865 842206
- HM 67 (27) approval for study leave

## New Brief Pulse ECT with Computer-Assisted Easy Seizure Monitoring



### Somatics Thymatron™ DGx

- Automatically monitors your choice of EEG-EEG, EEG-ECG, or EEG-EMG and determines EEG and motor seizure lengths.
- Computer-measured seizure quality, including postictal EEG suppression, seizure energy index.
- Up to 8 seconds stimulus duration; pulsewidth as short as 0.5 ms.
- Single dial sets stimulus charge by age; high-dose option available.
- FlexDial™ adjusts pulsewidth and frequency without altering dose.

Distributed in the U.K. by:  
DANTEC Electronics, Ltd.  
Garonor Way  
Royal Portbury  
Bristol BS20 9XE  
TEL (44) 1275-375333  
FAX (44) 1275-375336

Distributed in Australia by:  
MEECO Holdings Pty. Ltd.  
10 Seville St.  
North Parramatta NSW 2151  
Australia  
TEL (61) 2630-7755  
FAX (61) 2630-7365

Distributed in New Zealand by:  
WATSON VICTOR, Ltd.  
4 Adelaide Rd.  
Wellington, New Zealand  
TEL (64) 4-385-7699  
FAX (64) 4-384-4651

Distributed in Ireland by:  
BRENNAN & CO.  
Dublin  
TEL (353) 1-295-2501  
FAX (353) 1-295-2333

Distributed in India by:  
DIAGNO.SYS  
New Delhi  
TEL (91) 11-444-0546  
FAX (91) 11-422-9229

Distributed in South Africa by:  
DELTA SURGICAL  
Craigshall  
TEL (27) 11-792-6120  
FAX (27) 11-792-6926

Distributed in U.S.A. and Canada by:



**SOMATICS, INC.**, 910 Sherwood Drive # 17, Lake Bluff, IL, 60044, U.S.A.

Fax: (847) 234-6763; Tel: (847) 234-6761

## Plymouth Community Services NHS Trust (incorporating the Isles of Scilly)

### Lee Mill Residential Drug Service

A service for people with complex drug related problems

The service was opened in September 1996 for men, women and couples over the age of 16 years to offer an intensive short term response for:

- those people who wish to come off illicit drugs quickly but are unable to whilst at home;
- those whose drug use is out of control;
- those whose emotional or physical health is suffering as a result of drug use;
- those in crisis who need a safe environment in order to think and plan their future;
- those who are starting a substitute drug prescription under the care of their local drug agency or GP.

The service offers detoxification, crisis intervention, stabilisation, respite care and resettlement, in close co-ordination with specialist and non-specialist professionals in the client's local area.

The team has extensive experience in the management of all types of illicit drug use including cocaine, amphetamines, benzodiazepines and opiates and will initiate substitute prescribing if relevant to the agreed treatment plan.

**We are keen to admit people with physical or psychiatric illness alongside their drug use and will offer a detailed assessment of their needs, initiating treatment as necessary.**

Referrals are welcome via block booking or ECR. For further information please contact Ms Pauline Coldwell, Operational Manager, Lee Mill Residential Service, Beech Road, Lee Mill, Ivybridge, Devon PL21 9HL.

Tel: (01752) 896812. Fax: (01752) 896815.



**PLYMOUTH  
COMMUNITY SERVICES**  
NHS TRUST



## ATTENTION ALL CONSULTANT PSYCHIATRISTS

- \* We have long/short term positions available to start IMMEDIATELY.
- \* General/Adult/Old Age/Child & Family/Drug & Substance Abuse and Learning Disabilities.

**ALL AREAS**

**EXCELLENT RATES**

**IMMEDIATE STARTS**

**CASH PAYMENTS**

We have specialist staff waiting to hear from you in these areas:

**SOUTHAMPTON**

**MANCHESTER**

**& LONDON (M25 corridor)**

**DON'T DELAY**

### **Southern Division**

76 Portswood Road, Portswood,  
Southampton SO17 2FW  
Tel: 01703 393988; Fax: 01703 393908

### **Northern Division**

24-26 Brook Street, Chadderton,  
Oldham OL9 6NN  
Tel: 0161 2902020; Fax: 0161 2903030  
Email: direct@interalpha.co.uk

## **ORMSBY LODGE**

### *Consultancy*

Following the loss of Dr Albert Kuslick we are seeking a person to assist us in continuing our work with persons who have a learning disability together with challenging behaviours in residential and day care settings.

We have over the past nine years developed an expertise and tenacity of working with complex situations and we wish to maintain this high quality of care and therapeutic work on an individual basis.

We are seeking a person with expertise who can offer regular staff workshops and limited individual counselling assisting us to continue our Cognitive methods of working.

Commission and flexibility over timetabling is negotiable.

Contact David Clarke, tel & fax 01705 367956 or write to Ormsby Lodge, 1 Ormsby Road, Southsea, Hants PO5 2AL.

## **BBR MEDICAL EDUCATION**

**Formerly BPP Medical Education**

**Intensive weekend courses**

**MRCPsychiatry Parts I & II  
Written and Clinical skills courses**

**1998**

**Part I Written 14-15 March**

**Part II Written 14-15 March**

**Clinical 9-10 May**

**BBR Courses are  
Stimulating, entertaining and successful.**

**Telephone or Fax 0181-959-7562  
33 Flower Lane, Mill Hill, London NW7**

# Books Beyond Words

These books are joint publications between the Royal College of Psychiatrists and St. George's Hospital Medical School. They are intended for people with learning disabilities or difficulties or mental health needs. The stories are told through pictures alone to allow each reader to make his or her own interpretation. A short written text at the end of the book provides one possible narrative for the pictures. *Gaskell books are available from the Publications Department, Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG. (Tel. +44(0)171 235 2351, extension 146). Credit card orders can be taken over the telephone. The latest information on College publications is available on the INTERNET at: www.rcpsych.ac.uk*

## **You're under Arrest**

By Sheila Hollins, Isabel Clare and Glynis Murphy  
Illustrated by Beth Webb  
£10.00 72pp. 1996 ISBN 1 901242 01 3

## **You're on Trial**

By Sheila Hollins, Isabel Clare and Glynis Murphy  
Illustrated by Beth Webb  
£10.00 72pp. 1996 ISBN 901242 00 5

## **Going to Court**

By Sheila Hollins with Valerie Sinason and Julie Boniface  
Illustrated by Beth Webb  
£10.00 70pp. 1994 ISBN 1 874439 08 7

The pictures and text in these books are intended to show the likely events when someone with learning disabilities or mental health needs is under arrest and comes into contact with the criminal justice system. *Going to Court* is about being a witness in a Crown Court. The pictures suit any crime and any verdict.

## **Jenny Speaks Out**

£10.00 60pp. 1992 ISBN 1 874439 001

## **Bob Tells All**

£10.00 62pp. 1993 ISBN 1 874439 03 6

By Sheila Hollins and Valerie Sinason  
Illustrated by Beth Webb

These two companion books may enable a person with learning disabilities to open up about their experience of sexual abuse. Bob and Jenny have been abused and feel unsettled when they move to a new home in the community. In each story, the carers sensitively help Bob and Jenny unravel their painful past as victims of sexual abuse, to begin a slow but positive healing process.

## **Making Friends**

£10.00 68pp. 1995 ISBN 1 874439 10 9

## **Hug Me Touch Me**

£10.00 70pp. 1994 ISBN 1 874439 05 2

By Sheila Hollins and Terry Roth, illustrated by Beth Webb

The characters in these stories want to make new friends. The books show when they can and can't hug and touch other people. *Making Friends* tells the story from a man's perspective, while *Hug Me Touch Me* tells the story from a woman's point of view.

## **Feeling Blue**

By Sheila Hollins and Jenny Curran  
Illustrated by Beth Webb

This book is for people with learning disabilities who get depressed. It shows what happens to the character when he is depressed, and how he is helped to feel better.

£10.00 66pp. 1995 ISBN 1 874439 09 5



## **Michelle Finds a Voice**

By Sheila Hollins and Sarah Barnett  
Illustrated by Denise Redmond

This is the story of a young woman with cerebral palsy who is unable to speak, and so cannot communicate what she is feeling to the very people who might help her. The book shows how Michelle and her carers are helped to overcome these difficulties.  
1997 82pp ISBN 1-901242-06-4 £10.00

## **Going to the Doctor**

By Sheila Hollins, Jane Bernal and Matthew Gregory  
Illustrated by Beth Webb

Going to the doctor can be a worrying experience. For people with a learning disability, there is the added fear of not being able to explain what's wrong, as well as not understanding what's happening. Feelings, information and consent are all addressed. A variety of scenarios are covered (examination, blood test, prescription, etc.). Ideally, this book should be used to prepare someone before going to the doctor but it will also be invaluable to General Practitioners and primary health care workers during consultations and before treatments. £10.00 73pp. 1996 ISBN 1 874439 13 3

## **When Dad Died**

£10.00 60pp. 1989 ISBN 1 874439 06 0

## **When Mum Died**

£10.00 60pp. 1989 ISBN 1 874439 07 9

By Sheila Hollins and Lester Sireling  
Illustrated by Beth Webb

These two books take an honest and straightforward approach to death in the family. The pictures tell the story of the death of a parent in a simple but moving way. The approach is non-denominational. One book illustrates a cremation (*When Dad Died*), the other a burial. Children without learning disabilities will also appreciate these books which adopt a more direct approach to death than is usual.

## **A New Home in the Community**

£10.00 72pp. 1993 ISBN 1 874439 02 8

## **Peter's New Home**

£10.00 72pp. 1993 ISBN 1 874439 01 X

By Sheila Hollins and Deborah Hutchinson  
Illustrated by Beth Webb

These two books are designed to help people with learning disabilities make a happy transition to a new home. *Peter's New Home* tells the story of leaving one's family for a group home while *A New Home in the Community* tells the story of leaving a long-stay hostel or hospital to go to a group home.





A CANADIAN OPPORTUNITY

## PALLISER HEALTH AUTHORITY

MEDICINE HAT, ALBERTA

### URGENTLY REQUIRES

**ONE GENERAL PSYCHIATRIST**  
**ONE GENERAL PSYCHIATRIST with interest in PSYCHOGERIATRICS**  
**ONE CHILD PSYCHIATRIST**

To join a group of three Psychiatrists in the Medicine Hat Regional Hospital on a fee for service basis. MRCPsych is the minimum acceptable qualification.

The Palliser Health Authority serves a catchment area of 100,000 population with 45 Family Physicians and 45 Specialists.

Medicine Hat is located 288 km southeast of Calgary. It is a family oriented community offering full range of cultural, recreational and educational facilities.

Interviews will be held in London in May or June 1998.

Fax or write with C.V. and three references, before 30 April 1998, to: Dr Noorali Bharwani, FRCSC, FACS, Regional Chief of Staff, Palliser Health Authority, 666 - 5 Street S.W., Medicine Hat, Alberta, T1A 4H6, Canada. Tel.: 403-529-8024; Fax: 403-529-8998.

### SSR Medical Services *SPECIALISTS IN PSYCHIATRY*

Locum and substantive posts available  
in London and all major cities  
throughout the UK

We would be pleased to discuss  
the assignments currently available.

Please contact Liz Goodwin  
or her team on:-

**Telephone 0181 626 3117**

**Fax 0181 626 3101**

email: lgoodwin@ssrgroupservices.cix.co.uk

**We work for you,  
when you work for us.**

We are confident you will enjoy dealing  
with our professional, knowledgeable and  
caring consultants.



SSR Group Services  
5 Blackhorse Lane  
London E17 6DN



SSR Medical Services is a division of SSR Group Services Ltd

The

### XI World Congress of Psychiatry

will take place in **Hamburg, Germany**, from  
**6-11 August 1999**. Its theme will be 'Psychiatry  
on New Thresholds'.

Deadlines to remember:

- Submission of proposal for Symposia, Workshops and Courses **1 March 1998**
- Submission of proposal for Papers, Posters and Videos **31 December 1998**
- Early Registration for the Congress **1 February 1999**

For further information please contact:


**CPO Office Hamburg**  
**Hanser & Co GmbH**  
**Postbox 1221**  
**D-22882 Barsbüttel**  
**Germany**

**Telephone: +49 40 670 8820**  
**Telefax: +49 40 670 3283**  
**e-mail: cop@wpa-hamburg.de**

**Efexor<sup>®</sup> XL venlafaxine - Prescribing information Presentation:** Capsules containing 75mg or 150mg venlafaxine (as hydrochloride) in an extended release formulation. **Use:** Treatment of depressive illness. **Dosage:** Adults (including the elderly): Usually 75mg, given once daily with food, increasing to 150mg once daily if necessary. The dose can be increased further to 225mg once a day. Dose increments should be made at intervals of approximately 2 weeks or more, but not less than 4 days. Discontinue gradually to avoid possibility of discontinuation effects. **Children:** Contraindicated below 18 years of age. **Moderate renal or moderate hepatic impairment:** Doses should be reduced by 50%. Not recommended in severe renal or severe hepatic impairment. **Contra-indications:** Pregnancy, lactation, concomitant use with MAOIs, hypersensitivity to venlafaxine or other components, patients aged below 18 years. **Precautions:** Use with caution in patients with myocardial infarction, unstable heart disease, renal or hepatic impairment, or a history of epilepsy (discontinue in event of seizure). Patients should not drive

or operate machinery if their ability to do so is impaired. Possibility of postural hypotension (especially in the elderly). Women of child-bearing potential should use contraception. Prescribe smallest quantity of tablets according to good patient management. Monitor blood pressure with doses >200mg/day. Advise patients to notify their doctor should an allergy develop or if they become or intend to become pregnant. Patients with a history of drug abuse should be monitored carefully. **Interactions:** MAOIs: do not use Efexor XL in combination with MAOIs or within 14 days of stopping MAOI treatment. Allow 7 days after stopping Efexor XL before starting an MAOI. Use with caution in elderly or hepatically-impaired patients taking cimetidine, in patients taking other CNS-active drugs, and in patients taking drugs which inhibit both CYP2D6 and CYP3A4 hepatic enzymes. **Side-effects:** Nausea, insomnia, dry mouth, somnolence, dizziness, constipation, sweating, nervousness, asthenia, abnormal ejaculation/orgasm, anorexia, abnormal vision/accommodation, impotence, vomiting, tremor, abnormal

dreams, vasodilatation, hypertension, rash, agitation, hypertonia, paraesthesia, postural hypotension, reversible increases in liver enzymes, slight increase in serum cholesterol, weight gain or loss, hyponatraemia. **Basic NHS price:** 75mg capsule (PL 06011/0223) - blister pack of 28 capsules: £23.97. 150 mg capsule (PL 06011/0224) - blister pack of 28 capsules: £39.97. **Legal category:** POM. Further information is available upon request from the Product Licence holder: Wyeth Laboratories, Taplow, Maidenhead, Berkshire, SL6 0PH. Date of preparation: August 1997. \*trade mark Code no Z777440/0887. WEFX3-UK-JA. References: 1. Muth EA *et al*. *Biochem Pharmacol* 1986; 35(24): 4493-4497. 2. Muth EA *et al*. *Drug Development Research* 1991; 23: 191-199. 3. Rudolph R *et al*. Poster presented at the New Clinical Drug Evaluation Unit (National Institute of Mental Health), Boca Raton, Florida 1997. 4. McParlin GM *et al*. Poster at the 10th European College of Neuropsychopharmacology meeting, Vienna, September 13th-17th, 1997. 5. Salinas E. *Biol Psychiatry* 1997; 42(Suppl. 1): 244S.



Here  
comes the  
Sun

◆ EFEXOR XL ACTS DIRECTLY ON BOTH SEROTONIN AND NORADRENALINE<sup>1,2</sup>

◆ PROVEN EFFICACY VS LEADING SSRIs<sup>3,4</sup>

◆ TOLERABILITY<sup>3,4,5</sup> AND CONVENIENCE YOU EXPECT FROM A FIRST-LINE THERAPY

NEW ONCE DAILY


**EFEXOR XL<sup>®</sup>**  
VENLAFAXINE 75 mg o.d.

Simply effective



**Abbreviated Prescribing Information: PROVIGIL**  
 Please refer to summary of product characteristics before prescribing.  
**Presentation:** White to off white tablets each containing modafinil 100 mg. **Indication:** Narcolepsy. **Dosage:** Adults: 200-400 mg daily either as two divided doses in the morning and at noon or as a single morning dose according to response. **Usely:** Treatment should start at 100 mg daily which may be increased subsequently to the maximum adult daily dose in the absence of renal or hepatic impairment. **Severe renal or hepatic impairment:** Reduce dose by half (100-200 mg daily). **Children:** See contra-indications. **Contra indications:** Pregnancy, lactation, use in children, moderate to severe hypertension, arrhythmia, hypersensitivity to modafinil or any excipients used in Provigil. **Warnings and precautions:** Patients with major anxiety should only receive Provigil treatment in a specialist unit. Sexually active women of child bearing potential should be established on a contraceptive programme before starting treatment. Blood pressure and heart rate should be monitored in hypertensive patients. Provigil is not recommended in patients with a history of left ventricular hypertrophy or ischaemic ECG changes, chest pain, arrhythmia or other clinically significant manifestations of mitral valve prolapse in association with CNS stimulant use. Studies of modafinil have demonstrated a low potential for dependence although the possibility of this occurring with long term use cannot be entirely excluded. **Drug interactions:** Induction of cytochrome P-450 isoenzymes has been observed *in vitro*. Effectiveness of oral

contraceptives may be impaired when used with oral contraceptives containing at least 50 mcg ethinyloestradiol should be taken. Tricyclic antidepressants no clinically relevant interaction was seen in a single dose interaction study of Provigil and clomipramine. However, patients receiving such medication should be carefully monitored. Care should be observed with co administration of anti convulsant drugs. **Side effects:** Nervousness, excitation, aggressive tendencies, insomnia, personality disorder, anorexia, headache, CNS stimulation, euphoria, abdominal pain, dry mouth, palpitation, tachycardia, hypertension and tremor have been reported. Nausea and gastric discomfort may occur and may improve when tablets are taken with meals. Pruritic skin rashes have been observed occasionally. Buccofacial dyskinesia has been reported very rarely. A dose related increase in alkaline phosphatase has been observed. **Basic NHS cost:** Packs of 30 blister packed 100 mg tablets: £60.00. **Marketing authorisation number:** 16260/0001. **Marketing authorisation holder:** Cephalon UK Ltd, 11-13 Frederick Sanger Road, Surrey Research Park, Guildford, GU2 5YD. **Legal category:** POM. **Date of preparation:** January 1998. Provigil and Cephalon are registered trademarks. **References:** 1. Mitler MM. Sleep 1994; 17: S103-S106. 2. Data on file, Cephalon [3]. 3. Lin JS *et al*. *Proc Natl Acad Sci USA* 1996; 93: 14128-14133. 4. Simon P *et al*. *Eur Neuropsychopharmacol* 1995; 5: 509-514.



## WAKE UP LITTLE SUZIE, WAKE UP

Excessive sleepiness associated with narcolepsy frequently has a disastrous effect on patients' lives, by impairing their physical, social and emotional well being. Unfortunately, treatment with amphetamines is often associated with a high incidence of unpleasant side effects, which limit their overall benefit!

Now Provigil (modafinil) - a novel wake promoting agent - offers new advantages in narcolepsy. The clinical efficacy of Provigil has been demonstrated in large controlled clinical studies. In one study,<sup>2</sup> one in five people with severe narcolepsy reached normal levels of daytime wakefulness while receiving Provigil.

Provigil selectively activates the hypothalamus<sup>3</sup> and differs greatly from amphetamines in its pharmacology.<sup>4</sup> Consequently the incidence of amphetamine

**PROVIGIL®**  
**MODAFINIL**

#### RISPERDAL™ ABBREVIATED INFORMATION

Please refer to Summary of Product Characteristics before prescribing Risperdal (risperidone). **USES** The treatment of acute and chronic schizophrenia, and other psychotic conditions, in which positive and/or negative symptoms are prominent. Risperdal also alleviates affective symptoms associated with schizophrenia. **DOSAGE** Where medically appropriate, gradual discontinuation of previous antipsychotic treatment while Risperdal therapy is initiated is recommended. Where medically appropriate, when switching patients from depot antipsychotics, consider initiating Risperdal therapy in place of the next scheduled injection. The need for continuing existing antiparkinson medication should be re-evaluated periodically. **Adults:** Risperdal may be given once or twice daily. All patients, whether acute or chronic, should start with 2 mg/day. This should be increased to 4 mg/day on the second day and 6 mg/day on the third day. However, some patients such as first-episode psychotic patients may benefit from a slower rate of titration. From then on the dosage can be maintained unchanged, or further individualised if needed. The usual effective dosage is 4 to 8 mg/day although in some patients an optimal response may be obtained at lower doses. Doses above 10 mg/day may increase the risk of extrapyramidal symptoms and should only be used if the benefit is considered to outweigh the risk. Doses above 16 mg/day should not be used. **Elderly, renal and liver disease:** A starting dose of 0.5 mg bd is recommended. This can be individually adjusted with 0.5 mg bd increments to 1 to 2 mg bd. Risperdal is well tolerated by the elderly. Use with caution in patients with renal and liver disease. Not recommended in children aged less than 15 years.

**CONTRA-INDICATIONS, WARNINGS, ETC.** **Contra-indications:** Known hypersensitivity to Risperdal. **Precautions:** Orthostatic hypotension can occur (alpha-blocking effect). Use with caution in patients with known cardiovascular disease. Consider dose reduction if hypotension occurs. For further sedation, give an additional drug (such as a benzodiazepine) rather than increasing the dose of Risperdal. Drugs with dopamine antagonistic properties have been associated with tardive dyskinesia. If signs and symptoms of tardive dyskinesia appear, the discontinuation of all antipsychotic drugs should be considered. Caution should be exercised when treating patients with Parkinson's disease or epilepsy. Patients should be advised of the potential for weight gain. Risperdal may interfere with activities requiring mental alertness. Patients should be advised not to drive or operate machinery until their individual susceptibility is known. **Pregnancy and lactation:** Use during pregnancy only if the benefits outweigh the risks. Women receiving Risperdal should not breast feed. **Interactions:** Use with caution in combination with other centrally acting drugs. Risperdal may antagonise the effect of levodopa and other dopamine agonists. On initiation of carbamazepine or other hepatic enzyme-inducing drugs, the dosage of Risperdal should be re-evaluated and increased if necessary. On discontinuation of such drugs, the dosage of Risperdal should be re-evaluated and decreased if necessary. **Side effects:** Risperdal is generally well tolerated and in many instances it has been difficult to differentiate adverse events from symptoms of the underlying disease. Common adverse events include: insomnia, agitation, anxiety, headache. Less common adverse events include: somnolence, fatigue, dizziness, impaired concentration, constipation, dyspepsia, nausea/vomiting, abdominal pain, blurred vision, priapism, erectile dysfunction, ejaculatory dysfunction, orgasmic dysfunction, urinary incontinence, rhinitis, rash and other allergic reactions. The incidence and severity of extrapyramidal symptoms are significantly less than with haloperidol. However, the following may occur: tremor, rigidity, hypersalivation, bradykinesia, akathisia, acute dystonia. If acute, these symptoms are usually mild and reversible upon dose reduction and/or administration of antiparkinson medication. Rare cases of Neuroleptic Malignant Syndrome have been reported. In such an event, all antipsychotic drugs should be discontinued. Occasionally, orthostatic dizziness, hypotension (including orthostatic), tachycardia (including reflex) and hypertension have been observed. An increase in plasma prolactin concentration can occur which may be associated with galactorrhoea, gynaecomastia and disturbances of the menstrual cycle. Oedema and increased hepatic enzyme levels have been observed. A mild fall in neutrophil and/or thrombocyte count has been reported. Rare cases of water intoxication with hyponatraemia, tardive dyskinesia, body temperature dysregulation and seizures have been reported. **Overdosage:** Reported signs and symptoms include drowsiness and sedation, tachycardia and hypotension, and extrapyramidal symptoms. A prolonged QT interval was reported in a patient with concomitant hypokalaemia who had ingested 360 mg. Establish and maintain a clear airway, and ensure adequate oxygenation and ventilation. Gastric lavage and activated charcoal plus a laxative should be considered. Commence cardiovascular monitoring immediately, including continuous electrocardiographic monitoring to detect possible arrhythmias. There is no specific antidote, so institute appropriate supportive measures. Treat hypotension and circulatory collapse with appropriate measures. In case of severe extrapyramidal symptoms, give anticholinergic medication. Continue close medical supervision and monitoring until the patient recovers.

**PHARMACEUTICAL PRECAUTIONS** Tablets: Store below 30°C. Liquid: Store below 30°C; protect from freezing. **LEGAL CATEGORY POM. PRESENTATIONS, PACK SIZES, PRODUCT LICENCE NUMBERS & BASIC NHS COSTS** White, oblong tablets containing 1 mg risperidone in packs of 20. PL 0242/0186 £13.45. Pale orange, oblong tablets containing 2 mg risperidone in packs of 60. PL 0242/0187 £79.56. Yellow, oblong tablets containing 3 mg risperidone in packs of 60. PL 0242/0188 £117.00. Green, oblong tablets containing 4 mg risperidone in packs of 60. PL 0242/0189 £154.44. Yellow, circular tablets containing 6 mg risperidone in packs of 28. PL 0242/0317 £109.20. Starter packs containing 6 Risperdal 1 mg tablets are also available £4.15. Clear, colourless solution containing 1 mg risperidone per ml in bottles containing 100 ml. PL 0242/0189 £65.00. **FURTHER INFORMATION IS AVAILABLE FROM THE PRODUCT LICENCE HOLDER:** Janssen-Cilag Ltd, Saunderton, High Wycombe, Buckinghamshire HP14 4HJ. APIVER 140797. **References:** 1. Brecher M, Lammens P, Van Baelen B. Presented at the Annual Meeting of the American College of Neuropsychiatry, December 9-13, 1996, San Juan, Puerto Rico. 2. Data on file, Janssen-Cilag Ltd. MJE 12/97.

For the  
mind in  
tumors



**p e a c e**  
at last

- ▶ Power to relieve positive *and* negative symptoms in schizophrenia
- ▶ Placebo levels of EPS at usual effective doses<sup>1</sup>
- ▶ Over 18 million patient months experience worldwide<sup>2</sup>



**ONCE DAILY**  
**Risperdal**<sup>TM</sup>  
**RISPERIDONE**

**POWER you can trust**

# Change to

A woman with voluminous, curly brown hair is looking directly at the camera. Her face is partially obscured by a hand wearing a blue nitrile glove, which is positioned near her eye. The background is dark, and the lighting is dramatic, highlighting her hair and the texture of the glove.

## 'SEROQUEL' (quetiapine)

### Prescribing Notes.

**Consult Summary of Product Characteristics before prescribing**  
**Special reporting to the CSM required.**

**Use:** Treatment of schizophrenia.

**Presentation:** Tablets containing 25 mg, 100 mg and 200 mg of quetiapine.

**Dosage and Administration:** 'Seroquel' should be administered twice daily. Adults: The total daily dose for the

Elderly patients: Use with caution, starting with 25 mg/day and increasing daily by 25 to 50 mg to an effective dose.

Children and adolescents: Safety and efficacy not evaluated.

Renal and hepatic impairment: Start with 25 mg/day

increasing daily by 25 to 50 mg to an effective dose.

Use with caution in patients with hepatic impairment.

**Contra-indications:** Hypersensitivity to any component of the product.

**Precautions:** Caution in patients with cardiovascular disease, cerebrovascular disease or other conditions predisposing to hypotension and patients with a history of seizures. Caution with drugs known to prolong the QTc interval, especially in the elderly. Caution in combination

systemic ketoconazole or erythromycin. If signs and symptoms of tardive dyskinesia appear, consider dosage reduction or discontinuation of 'Seroquel'. In cases of neuroleptic malignant syndrome, discontinue 'Seroquel' and give appropriate medical treatment. 'Seroquel' should only be used during pregnancy if benefits justify the potential risks. Avoid breastfeeding whilst taking 'Seroquel'. Patients should be cautioned about operating hazardous machines, including motor vehicles.

**Undesirable events:** Somnolence, dizziness, constipation, postural hypotension, dry mouth, asthma, rhinitis, dyspepsia, limited weight gain, orthostatic hypotension (associated with dizziness), tachycardia and in some patients syncope. Occasional seizures and rarely possible neuroleptic malignant

NEW

# Seroquel

quetiapine

- Effective in positive and negative symptoms<sup>1-4</sup> and improving mood\*<sup>5</sup> in patients with schizophrenia
- Incidence of EPS no different from placebo across the full dose range<sup>1-4</sup>
- Rate of withdrawals due to adverse events no different from placebo<sup>6</sup>
- No requirement for routine blood, BP or ECG monitoring<sup>7</sup>



*Changing thinking in schizophrenia.*

\* Defined as the BPRS item scores of depressive mood, anxiety, guilt feelings and tension

Small elevations in non-fasting serum triglyceride levels and total cholesterol. Decreases in thyroid hormone levels, particularly total T4 and free T4 usually reversible on cessation. Prolongation of the QTc interval (in clinical trials this was not associated with a persistent increase).

Legal category: POM

Product licence numbers:

25 mg tablet: 12619/0112

100 mg tablet: 12619/0113

400 mg tablet: 12619/0114

Basic NHS cost:

100 mg x 28 tablets / 113.10

400 mg x 28 tablets / 169.65

Further information is available from:

ZENECA Pharma on 0800 200 123 please ask for Medical Information, or write to King's Court, Water Lane, Wilmslow, Cheshire SK9 5AZ.



© 1997 Zeneca Pharmaceuticals

#### References

1. Fabre LF, Arvanitis L, Pultz J *et al.* Clin Ther 1995; **17** (No.3): 366-378.
2. Arvanitis LA *et al.* Biol Psychiatry 1997; **42**: 233-246.
3. Small JG, Hirsch SR, Arvanitis LA *et al.* Arch Gen Psychiatry 1997; **54**: 549-557.
4. Borison RL, Arvanitis LA, Miller MS *et al.* J Clin Psychopharmacol 1996; **16** (2):158-169.
5. Data on File, Zeneca Pharmaceuticals.
6. Data on File, Zeneca Pharmaceuticals.
7. 'Seroquel' Summary of Product Characteristics.



# Add life to living with schizophrenia

Solian is a new benzamide antipsychotic, with the ability to treat both the positive<sup>1</sup> and negative<sup>2</sup> symptoms of schizophrenia.

Solian offers a lower incidence of EPS than standard neuroleptics such as haloperidol,<sup>3</sup> as well as avoiding some of the drawbacks of certain atypicals: it does not require routine cardiovascular<sup>4,5</sup> or haematological<sup>4,6</sup>

monitoring and patients gain significantly less weight than those treated with risperidone.<sup>2</sup>

So when patients need the ability to cope with their condition, Solian has the power to treat their positive<sup>1</sup> and their negative<sup>2</sup> symptoms whilst still allowing them to do the everyday things that the rest of us take for granted.

**Solian**<sup>®</sup>  
AMISULPRIDE



Efficacy that patients can live with

**Prescribing Information - Solian 200 and Solian 50** ▼ **Presentation:** Solian 200mg tablets contain 200mg amisulpride and Solian 50mg tablets contain 50mg amisulpride. **Indication:** Acute and chronic schizophrenia in which positive and/or negative symptoms are prominent. **Dosage:** Acute psychotic episodes: 400-800mg/day, increasing up to 1200mg/day according to individual response (dose titration not required), in divided doses. Predominantly negative symptoms: 50-300mg once daily adjusted according to individual response. Elderly: administer with caution due to the risk of hypotension or sedation. Renal insufficiency: reduce dose and consider intermittent therapy. Hepatic insufficiency: no dosage adjustment necessary. Children: contraindicated in children under 15 years (safety not established). **Contraindications:** Hypersensitivity; concomitant prolactin-dependent tumours e.g. pituitary gland prolactinaemias and breast cancer; phaeochromocytoma; children under 15 years; pregnancy; lactation; women of childbearing potential unless using adequate contraception. **Warning and Precautions:** As with all neuroleptics, neuroleptic malignant syndrome may occur (discontinue Solian). Caution in patients with a history of epilepsy and Parkinson's disease. **Interactions:** Caution in

hypotensive medications, and dopamine agonists. **Side Effects:** Insomnia, anxiety, agitation. Less commonly somnolence and GI disorders. In common with other neuroleptics: Solian causes a reversible increase in plasma prolactin levels; Solian may also cause weight gain, acute dystonia, extrapyramidal symptoms, tardive dyskinesia, hypotension and bradycardia; rarely, allergic reactions, seizures and neuroleptic malignant syndrome have been reported. **Basic NHS Cost:** Blister packs of: 200mg x 60 tablets - £60.00; 200mg x 90 tablets - £90.00; 50mg x 60 tablets - £16.45; 50mg x 90 tablets - £24.69. **Legal Category:** POM. **Product Licence Numbers:** Solian 200 - PL 15819/0002, Solian 50 - PL 15819/0001. **Product Licence Holder:** Lorex Synthelabo UK and Ireland Ltd, Foundation Park, Roxborough Way, Maidenhead, Berks, SL6 3UD. **References:** 1. Freeman HL. *Int Clin Psychopharmacol* 1997;12(Suppl 2):S11-S17. 2. Möller HJ. 6th World Congress of Biological Psychiatry, Nice, France, June 22-27 1997. 3. Coukell AJ, Spencer CM, Benfield P. *CNS Drugs (Adis)* 1996 Sep 6 (3):237-256. 4. Solian SPC. Lorex Synthelabo. 5. Sertindole SPC Lundbeck Ltd. 6. Clozapine SPC.

SYNTHELABO  
CNS DIVISION

# Mum has Alzheimer's



- **The first selective treatment** for the symptoms of mild to moderately severe Alzheimer's dementia licensed in the UK <sup>1,2</sup>
- **Improvements** in cognitive symptoms and global function <sup>3-5</sup>
- **Simple** once daily dosage
- **Well tolerated.** <sup>6</sup>

but she knew I was calling today

**new** ● **once daily**  
**Aricept**<sup>®</sup>  
donepezil hydrochloride



**A first step in Alzheimer's**

#### BRIEF PRESCRIBING INFORMATION

ARICEPT<sup>®</sup> (donepezil hydrochloride)  
Please refer to the SmPC before prescribing ARICEPT 5mg or ARICEPT 10mg. **Indication:** Symptomatic treatment of mild to moderately severe Alzheimer's dementia. **Dose and administration:** *Adults/elderly:* 5mg daily which may be increased to 10mg once daily after at least one month. No dose adjustment necessary for patients with renal or mild-moderate hepatic impairment. **Children:** Not recommended. **Contraindications:** Hypersensitivity to donepezil, piperidine derivatives or any excipients used in ARICEPT. **Pregnancy, Lactation:** Excretion into breast milk unknown. Women on donepezil should not breast feed. **Warnings and Precautions:** Initiation and supervision by a physician with experience of Alzheimer's dementia. A caregiver should be available to monitor for adverse effects. **Side effects:** Most commonly diarrhoea, muscle cramps, fatigue, nausea, vomiting and insomnia. Other common effects in clinical trials (SEs) and

antagonists. Possibility of vagotonic effect on the heart which may be particularly important with "sick sinus syndrome" and supraventricular conduction conditions. Careful monitoring of patients at risk of ulcer disease including those receiving NSAIDs. Cholinomimetics may cause bladder outflow obstruction. Seizures occur in Alzheimer's disease and cholinomimetics have the potential to cause seizures. Care in patients suffering asthma and obstructive pulmonary disease. As with all Alzheimer's patients, routine evaluation of ability to drive/operate machinery. **Drug Interactions:** Experience of use with concomitant medications is limited, consider possibility of as yet unknown interactions. Interaction possible with inhibitors or inducers of Cytochrome P450: use such combinations with care. Possible synergistic activity with succinylcholine-type muscle relaxants, beta-blockers, and centrally acting anticholinergic agents. **Side effects:** Most commonly diarrhoea, muscle cramps, fatigue, nausea, vomiting and insomnia. Other common effects in clinical trials (SEs) and

heart block. Minor increases in muscle creatine kinase. **Presentation and basic NHS cost:** Blister packed in strips of 14. ARICEPT 5mg; white, film coated tablets marked 5 and ARICEPT, packs of 28 £68.32. ARICEPT 10mg; yellow, film coated tablets marked 10 and ARICEPT, packs of 28 £95.76. **Marketing authorisation numbers:** ARICEPT 5 mg; PL 10555/0006. ARICEPT 10mg; PL 10555/0007. **Marketing authorisation holder:** Eisai Ltd. **Further information from/Marketed by:** Eisai Ltd, Hammersmith International Centre, 3 Shortlands, London, W6 8EE and Pfizer Ltd, Sandwich, Kent, CT13 9NJ. **Legal category:** POM **Date of preparation:** August 1997. **References:** 1. Kelly CA et al. Br Med J 1997; 314: 693-694. 2. Rogers SL et al. In: Becker R, Giacobini E, eds. Cholinergic Basis for Alzheimer Therapy. Boston: Birkhauser; 1991: 314-320. 3. Data on file (A301). 4. Data on file (A302) and Rogers SL et al. Neurology 1996; 46: A217. 5. Rogers SL et al. Dementia 1996; 7: 203-207. 6. Data on file. **Interacted**



GASKELL

# Bereavement Information Pack

For those bereaved  
through suicide or other  
sudden death

*Kate Hill, Keith Hawton,  
Aslög Malmberg and Sue Simkin*

It is often difficult for relatives and friends of people who die by suicide or other sudden death to get help. This pack is specifically designed for such people. It highlights the areas of greatest difficulty for the bereaved person and offers advice on how to get support from friends and family and bereavement support and counselling organisations, as well as providing a list of recommended reading. A substantial number of bereaved individuals have already found it helpful. This pack is fully supported by The Samaritans and The Royal College of Psychiatrists.

● £5.00 ● 1997 ● ISBN 1 901242 08 0

*Gaskell is the imprint of the Royal College of Psychiatrists. Gaskell books are available from good bookshops and from Book Sales, Publications Department, Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG (Tel. +44(0)171 235 2351, extension 146). The latest information on College publications is available on the INTERNET at: [www.rcpsych.ac.uk](http://www.rcpsych.ac.uk)*

## ZISPIN Prescribing Information

**Presentation:** Blister strips of 28 tablets each containing 30 mg of mirtazapine. **Uses:** Treatment of depressive illness. **Dosage and administration:** The tablets should be taken orally, if necessary with fluid, and swallowed without chewing. **Adults and elderly:** The effective daily dose is usually between 15 and 45 mg. **Children:** Not recommended. The clearance of mirtazapine may be decreased in patients with renal or hepatic insufficiency. Zispin is suitable for once-a-day administration, preferably as a single night-time dose. Treatment should be continued until the patient has been completely symptom-free for 4 - 6 months. **Contraindications:** Hypersensitivity to mirtazapine or any ingredients of Zispin. **Precautions and warnings:** Reversible white blood cell disorders including agranulocytosis, leukopenia and granulocytopenia have been reported with Zispin. The physician should be alert to symptoms such as fever, sore throat, stomatitis or other signs of infection; if these occur, treatment should be stopped and blood counts taken. Patients should also be advised of the importance of these symptoms. Careful dosing as well as regular and close monitoring is necessary in patients with: epilepsy and organic brain syndrome; hepatic or renal insufficiency; cardiac diseases; low blood pressure. As with other antidepressants care should be taken in patients with: micturition disturbances like prostate hypertrophy, acute narrow-angle glaucoma and increased intra-ocular pressure and diabetes mellitus. Treatment should be discontinued if jaundice occurs. Moreover, as with other antidepressants, the following should be taken into account: worsening of psychotic symptoms can occur when antidepressants are administered to patients with schizophrenia or other psychotic disturbances; when the depressive phase of manic-depressive psychosis is being treated, it can transform into the manic phase. Zispin has sedative properties and may impair concentration and alertness. **Interactions:** Mirtazapine may potentiate the central nervous dampening action of alcohol; patients should therefore be advised to avoid alcohol during treatment with Zispin; Zispin should not be administered concomitantly with MAO inhibitors or within two weeks of cessation of therapy with these agents; Mirtazapine may potentiate the sedative effects of benzodiazepines; In vitro data suggest that clinically significant interactions are unlikely with mirtazapine. **Pregnancy and lactation:** The safety of Zispin in human pregnancy has not been established. Use during pregnancy is not recommended. Women of child bearing potential should employ an adequate method of contraception. Use in nursing mothers is not recommended. **Adverse reactions:** The following adverse effects have been reported: **Common (> 1/100):** Increase in appetite and weight gain. Drowsiness/sedation, generally occurring during the first few weeks of treatment. (N.B. dose reduction generally does not lead to less sedation but can jeopardize antidepressant efficacy). **Less common:** Increases in liver enzyme levels. **Rare (< 1/1000):** Oedema and accompanying weight gain. Reversible agranulocytosis has been reported as a rare occurrence. (Orthostatic) hypotension. Exanthema. Mania, convulsions, tremor, myoclonus. **Overdosage:** Toxicity studies in animals suggest that clinically relevant cardiotoxic effects will not occur after overdosing with Zispin. Experience in clinical trials and from the market has shown that no serious adverse effects have been associated with Zispin in overdose. Symptoms of acute overdosage are confined to prolonged sedation. Cases of overdose should be treated by gastric lavage with appropriate symptomatic and supportive therapy for vital functions. **Marketing authorization number:** PL 0065/0145 **Legal category:** POM **Basic NHS cost:** £24 for 28 tablets of 30 mg.



For further information, please contact:  
Organon Laboratories Limited, Cambridge Science  
Park, Milton Road, Cambridge CB4 4FL  
Telephone: 01223 423445. Fax: 01223 424368.



MIRTAZAPINE

**ZISPIN** 30<sup>▼</sup> mg

The NaSSA

**Strong  
yet  
gentle**

in

depression



# CLOZARIL<sup>®</sup>

clozapine


## CLOZARIL ABBREVIATED PRESCRIBING INFORMATION.

The use of CLOZARIL is restricted to patients registered with the CLOZARIL Patient Monitoring Service. Indication Treatment-resistant schizophrenia (patients non-responsive to, or intolerant of, conventional neuroleptics). Presentations 25mg and 100 mg clozapine tablets. Dosage and Administration Initiation must be in hospital in-patients and is restricted to patients with normal white blood cell and differential counts. Initially, 12.5 mg once or twice on the first day, followed by one or two 25 mg tablets on the second day. Increase dose slowly, by increments to reach a therapeutic dose within the range of 200 - 450mg daily (see data sheet). The total daily dose should be divided and a larger portion of the dose may be given at night. Once control is achieved a maintenance dose of 150 to 300 mg daily may suffice. At daily doses not exceeding 200mg, a single administration in the evening may be appropriate. Exceptionally, doses up to 900 mg daily may be used. Patients with a history of epilepsy should be closely monitored during CLOZARIL therapy since dose-related convulsions have been reported. Patients with a history of seizures, as well as those suffering from cardiovascular, renal or hepatic disorders, together with the elderly need lower doses (12.5 mg given once on the first day) and more gradual titration. Contra-Indications Allergy to any constituents of the formulation. History of drug-induced neutropenia/agranulocytosis, myeloproliferative disorders, uncontrolled epilepsy, alcoholic and toxic psychoses, drug intoxication, comatose conditions, circulatory collapse and/or CNS depression of any cause, severe renal or cardiac failure, active liver disease, progressive liver disease or hepatic failure. Warning CLOZARIL can cause agranulocytosis. A fatality rate of up to 1 in 300 has been estimated when CLOZARIL was used prior to recognition of this risk. Since that time strict haematological monitoring of patients has been demonstrated to be effective in markedly reducing the risk of fatality. Therefore, because of this risk its use is limited to treatment-resistant schizophrenic patients:- 1. who have normal leucocyte findings and 2. in whom regular leucocyte counts can be performed weekly during the first 18 weeks and at least every two weeks thereafter for the first year of therapy. After one year's treatment, monitoring may be changed to four weekly intervals in patients with stable neutrophil counts. Monitoring must continue throughout treatment and for four weeks after complete discontinuation of CLOZARIL. Patients must be under specialist supervision and CLOZARIL supply is restricted to pharmacies registered with the CLOZARIL Patient Monitoring Service. Prescribing physicians must register themselves, their patients and a nominated pharmacist with the CLOZARIL Patient Monitoring Service. This service provides for the required leucocyte counts as well as a drug supply audit so that CLOZARIL treatment is promptly withdrawn from any patient who develops abnormal leucocyte findings. Each time CLOZARIL is prescribed, patients should be reminded to contact the treating physician immediately if any kind of infection begins to develop, especially any flu-like symptoms. Precautions CLOZARIL can cause agranulocytosis. Perform pre-treatment white blood cell count and differential count to ensure only patients with normal findings receive CLOZARIL. Monitor white blood cell count weekly for the first 18 weeks and at least two-weekly for the first year of therapy. After one year's treatment, monitoring may change to four weekly intervals in patients with stable neutrophil counts. Monitoring must continue throughout treatment and for four weeks after complete discontinuation. If signs or symptoms of infection develop an immediate differential count is necessary. If the white blood count falls below  $3.0 \times 10^9/L$  and/or the absolute neutrophil count drops below  $1.5 \times 10^9/L$ , withdraw CLOZARIL immediately and monitor the patient closely, paying particular attention to symptoms suggestive of infection. Re-evaluate any patient developing an infection, or when a routine white blood count is between  $3.0$  and  $3.5 \times 10^9/L$  and/or a neutrophil count between  $1.5$  and  $2.0 \times 10^9/L$ , with a view to discontinuing CLOZARIL. Any further fall in white blood/neutrophil count below  $1.0 \times 10^9/L$  and/or  $0.5 \times 10^9/L$  respectively, after drug withdrawal requires immediate specialised care, where protective isolation and administration of GM-CSF or G-CSF and broad spectrum antibiotics may be indicated. Colony stimulating factor therapy should be discontinued when the neutrophil count returns above  $1.0 \times 10^9/L$ . CLOZARIL lowers the seizure threshold. Orthostatic hypotension can occur therefore close medical supervision is required during initial dose titration. Patients affected by the sedative action of CLOZARIL should not drive or

operate machinery, administer with caution to patients who participate in activities requiring complete mental alertness. Monitor hepatic function regularly in liver disease. Investigate any signs of liver disease immediately with a view to drug discontinuation. Resume only if LFTs return to normal, then closely monitor patient. Use with care in prostatic enlargement, narrow-angle glaucoma and paralytic ileus. Patients with fever should be carefully evaluated to rule out the possibility of an underlying infection or the development of agranulocytosis. Avoid immobilisation of patients due to increased risk of thromboembolism. Do not give CLOZARIL with other drugs with a substantial potential to depress bone marrow function. CLOZARIL may enhance the effects of alcohol, MAO inhibitors, CNS depressants and drugs with anticholinergic, hypotensive or respiratory depressant effects. Caution is advised when CLOZARIL therapy is initiated in patients who are receiving (or have recently received) a benzodiazepine or any other psychotropic drug as these patients may have an increased risk of circulatory collapse, which, on rare occasions, can be profound and may lead to cardiac and/or respiratory arrest. Caution is advised with concomitant administration of therapeutic agents which are highly bound to plasma proteins. Clozapine binds to and is partially metabolised by the isoenzymes cytochrome P450 1A2 and P450 2D6. Caution is advised with drugs which possess affinity for these isoenzymes. Concomitant cimetidine and high dose CLOZARIL was associated with increased plasma clozapine levels and the occurrence of adverse effects. Concomitant fluoxetine and fluvoxamine have been associated with elevated clozapine levels. Discontinuation of concomitant carbamazepine resulted in increased clozapine levels. Phenytoin decreases clozapine levels resulting in reduced effectiveness of CLOZARIL. No clinically relevant interactions have been noted with antidepressants, phenothiazines and type Ic antiarrhythmics, to date. Concomitant use of lithium or other CNS-active agents may increase the risk of neuroleptic malignant syndrome. The hypertensive effect of adrenaline and its derivatives may be reversed by CLOZARIL. Do not use in pregnant or nursing women. Use adequate contraceptive measures in women of child bearing potential. Side-Effects Neutropenia leading to agranulocytosis (See Warning and Precautions). Rare reports of leucocytosis including eosinophilia. Isolated cases of leukaemia and thrombocytopenia have been reported but there is no evidence to suggest a causal relationship with the drug. Most commonly fatigue, drowsiness, sedation. Dizziness or headache may also occur. CLOZARIL lowers the seizure threshold and may cause EEG changes and delirium. Myoclonic jerks or convulsions may be precipitated in individuals who have epileptogenic potential but no previous history of epilepsy. Rarely it may cause confusion, restlessness, agitation and delirium. Extrapyrarnidal symptoms are limited mainly to tremor, akathisia and rigidity. Tardive dyskinesia reported very rarely. Neuroleptic malignant syndrome has been reported. Transient autonomic effects eg dry mouth, disturbances of accommodation and disturbances in sweating and temperature regulation. Hypersalivation. Tachycardia and postural hypotension, with or without syncope, and less commonly hypertension may occur. In rare cases profound circulatory collapse has occurred. ECG changes, arrhythmias, pericarditis and myocarditis (with or without eosinophilia) have been reported, some of which have been fatal. Rare reports of thromboembolism. Isolated cases of respiratory depression or arrest, with or without circulatory collapse. Rarely aspiration may occur in patients presenting with dysphagia or as a consequence of acute overdosage. Nausea, vomiting and usually mild constipation have been reported. Occasionally obstipation and paralytic ileus have occurred. Asymptomatic elevations in liver enzymes occur commonly and usually resolve. Rarely hepatitis and cholestatic jaundice may occur. Very rarely fulminant hepatic necrosis reported. Discontinue CLOZARIL if jaundice develops. Rare cases of acute pancreatitis have been reported. Both urinary incontinence and retention and priapism have been reported. Isolated cases of interstitial nephritis have occurred. Benign hyperthermia may occur and isolated reports of skin reactions have been received. Rarely hyperglycaemia has been reported. Rarely increases in CPK values have occurred. With prolonged treatment considerable weight gain has been observed. Sudden unexplained deaths have been reported in patients receiving CLOZARIL. Package Quantities and Price Community pharmacies only 28 x 25mg tablets: £12.52 (Basic NHS) 28 x 100mg tablets: £50.05 (Basic NHS) Hospital pharmacies only 84 x 25 mg tablets: £37.54 (Basic NHS) 84 x 100 mg tablets: £150.15 (Basic NHS) Supply of CLOZARIL is restricted to pharmacies registered with the CLOZARIL Patient Monitoring Service. Product Licence Numbers 25 mg tablets: PL 0101/0228 100 mg tablets: PL 0101/0229 Legal Category: POM. CLOZARIL is a registered Trade Mark. Date of preparation, August 1997. Full prescribing information, including Product Data Sheet is available from Novartis Pharmaceuticals UK Ltd. Trading as: SANDOZ PHARMACEUTICALS, Frimley Business Park, Frimley, Camberley, Surrey, GU16 5SG.

 NOVARTIS

AUG'97 CLZ 97/13

A man with dark, wavy hair, wearing a white lab coat, is looking directly at the camera with a slight smile. The background is a gradient of blue and yellow. The text is overlaid on the image.

As the list of  
antipsychotic  
agents grows...

...isn't it time to  
consider one in  
a different class?

**CLOZARIL<sup>®</sup>**  
clozapine

Proven efficacy in treatment  
resistant schizophrenia

Prescribed by  
97% of psychiatrists



# Fast Response

Can start to improve symptoms within seven days



**A first choice antidepressant**



**Abbreviated Prescribing Information: Lustral (sertraline)**

**Presentation:** Tablets containing 50mg or 100mg sertraline. **Indications:** Treatment of symptoms of depressive illness, including accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes, including accompanying symptoms of anxiety. **Dosage:** Lustral should be given as a single daily dose. The initial dose is 50mg and the usual therapeutic dose is 50mg daily. Dosage can be further increased, if appropriate, to a maximum of 200mg daily. Patients should be maintained on the lowest effective dose. Lustral should not be used for periods exceeding 8 weeks. **Use in children:**

least 14 days should elapse before starting any MAOI following discontinuation of Lustral. **Use during pregnancy:** Lustral should be used only if clearly needed. **Lactation:** Not recommended. **Precautions, warnings:** Renal insufficiency, unstable epilepsy, ECT, driving. Lustral should be discontinued in a patient who develops seizures. Lustral should not be administered to patients concurrently being treated with tranquilizers who drive or operate machinery. Patients should be closely supervised for the possibility of suicide attempt or activation of mania/hypomania. **Drug Interactions:** Caution with other centrally active medication. Serotonergic drugs including tryptophan, sumatriptan and fenfluramine should not be used with Lustral. Lithium levels should be monitored. Although Lustral has been shown to have no adverse effect on alcohol, concomitant use with alcohol is not recommended. Interactions with other highly protein bound drugs

Lustral is initiated or stopped. **Side-Effects:** Dry mouth, nau- diarrhoea/loose stools, ejaculatory delay, tremor, increa sweating, dyspepsia, dizziness, insomnia and somnolence. Rare abnormal LFTs, hyponatraemia. Malaise and rash have been reported. Seizures (see precautions, warnings). The following have been reported with Lustral but may have no causal relationship: movement disorders, menstrual irregularities, hyperprolactinaemia, galactorrhoea. As with all psychoactive medicines, possible side effects on discontinuation. **Legal Category:** POM. **Basic NHS Cost:** 50 tablet (PL57/0308) Calendar pack of 28, £26.51; 100mg tablet. 57/0309) Calendar pack of 28, £39.77. Further information on request Invicta™ Pharmaceuticals or Richborough™ Pharmaceuticals Division of Pfizer Limited, Sandwich, Kent. Date of preparation: June 1997

# Another seizure-free day

Wasn't late getting up

Didn't let fish off hook

Didn't fall in water

Didn't have a seizure

 **TOPAMAX**<sup>®</sup>  
topiramate

At the end of the day, it works.

adjunctive treatment for partial seizures with or without secondary generalisation

#### TOPAMAX Abbreviated Prescribing Information Please read the data sheet before prescribing

**Indication:** Tablets each imprinted "TOP" on one side and strength on the other containing 25mg (white), 50mg (light yellow), 100mg (yellow), and 200mg (salmon) topiramate. **Uses:** adjunctive therapy of partial seizures, with or without secondarily generalised seizures, in patients inadequately controlled on conventional first line antiepileptic drugs. **Dosage and Administration:** Adults and Elderly: Oral administration. Usual dose: 200mg - 400mg/day in two divided doses. Maximum recommended dose: 800mg/day. Initiate therapy at 50mg bd then titrate to an effective dose. See data sheet for titration. Do not break tablets. It is not necessary to monitor topiramate plasma concentrations. Patients with renal disease/haemodialysis may require a modified titration schedule. (See data sheet). Children: Not recommended. **Contra-Indications:** hypersensitivity to any component of the product. **Precautions and Warnings:** Withdraw all antiepileptic drugs gradually. Maintain adequate hydration to reduce risk of nephrolithiasis especially increased in those with a predisposition). Drowsiness likely. TOPAMAX may be more sedating than other antiepileptic drugs therefore caution in patients driving or operating machinery, particularly until patients' experience with the drug is established. Do not use in pregnancy unless potential benefit outweighs risk to foetus. Women of child bearing potential should use adequate contraception. Do not use if breastfeeding. **Interactions:** Other Antiepileptic Drugs: No clinically

plasma concentrations on sodium valproate addition or withdrawal. Digoxin: A decrease in serum digoxin occurs. Monitor serum digoxin on addition or withdrawal of TOPAMAX. Oral Contraceptives: Should contain not less than 50µg of oestrogen. Ask patients to report any change in bleeding patterns. Others: Avoid agents predisposing to nephrolithiasis. **Side Effects:** In 5% or more: ataxia, impaired concentration, confusion, dizziness, fatigue, paraesthesia, somnolence and abnormal thinking. May cause agitation and emotional lability (which may manifest as abnormal behaviour) and depression. Less commonly: amnesia, anorexia, aphasia, diplopia, nausea, nystagmus, speech disorder, taste perversion, abnormal vision and weight decrease. Increased risk of nephrolithiasis. Venous thromboembolic events reported - causal association not established. **Overdose:** If ingestion recent, empty stomach. Activated charcoal not recommended. Supportive treatment as appropriate. Haemodialysis is effective in removing topiramate. **Pharmaceutical Precautions:** Store in a dry place at or below 25°C. **Legal Category:** POM **Package Quantities and Prices:** Bottles of 60 tablets. 25mg (PL0242/0301) = £22.02; 50mg (PL0242/0302) = £36.17; 100mg (PL0242/0303) = £64.80; 200mg (PL0242/0304) = £125.83. **Product Licence Holder:** JANSSEN-CILAG LIMITED, SAUNDERTON, HIGH WYCOMBE, BUCKINGHAMSHIRE HP14 4HJ. API VER 210397. Further information is available on request from the Marketing Authorisation Holder: Janssen-Cilag Limited, Saunderton, High Wycombe, Buckinghamshire HP14 4HJ



# There's a depressed patient sitting in front of you. Ask them if it's good to talk.

**C**ommunicating confidently, whether it's at work or with friends and family, is just one sign of how well a depressed patient is re-adapting socially. And social interaction is an extremely valuable measure of successful treatment.

**Edronax is a new selective NorAdrenaline Re-uptake Inhibitor (NARI). It not only lifts depressed mood,<sup>1</sup> but also significantly improves social interaction.<sup>2</sup>**

These improvements in social functioning have been trial-proven by using the innovative SASS questionnaire (Social Adaptation Self-evaluation Scale).<sup>3</sup>

Edronax improves mood one week earlier than fluoxetine.<sup>1</sup> Additionally, when compared to fluoxetine, Edronax shows a significantly better outcome in terms of social functioning.<sup>2</sup>

Edronax helps restore patients' appreciation of friends, family, work and hobbies, and improves their self-perception.

Prescribe 4mg b.d. then make your usual assessments, to see the Edronax difference. The SASS questionnaire, which patients can complete in their own time, may also help.

**For free copies of the SASS questionnaire, please telephone 01908 603083.**

  
**Edronax<sup>®</sup>**  
**REBOXETINE**


**A NEW SELECTIVE NARI. LIFTS DEPRESSION.  
HELPS RESTORE SOCIAL INTERACTION.**

**EDRONAX<sup>®</sup>**  
**ABBREVIATED PRESCRIBING INFORMATION**  
**Presentation:** Tablets containing 4mg reboxetine. **Indications:** Use in the acute treatment of depressive illness, and maintenance of clinical benefit in patients responsive to treatment. **Posology and method of administration:** Adults 4 mg b.i.d. (8 mg/day) administered orally. After 3-4 weeks, can increase to 10 mg/day. **Elderly and children** Elderly patients have been studied in comparative clinical trials at doses of 2 mg b.i.d., although not in placebo controlled conditions. There is no experience in children and therefore reboxetine cannot be recommended in either of these groups. **Renal/Hepatic**

**Special warnings and precautions for use:** Close supervision is required for subjects with a history of convulsive disorders and must be discontinued if the patient develops seizures. Avoid concomitant use with MAO inhibitors. Close supervision of bipolar patients is recommended. Close supervision should be applied in patients with current evidence of urinary retention, glaucoma, prostatic hypertrophy and cardiac disease. At doses higher than the maximum recommended, orthostatic hypotension has been observed with greater frequency. Particular attention should be paid when administering reboxetine with other drugs known to lower blood pressure. **Interactions with other medications**

that have a narrow therapeutic margin and are metabolised by CYP3A4 or CYP2D6 e.g. anti-arrhythmics (flecainide), anti-psychotic drugs and tricyclic anti-depressants. No pharmacokinetic interaction with lorazepam. Reboxetine does not appear to potentiate the effect of alcohol. **Pregnancy and lactation:** Reboxetine is contraindicated in pregnancy and lactation. **Effects on ability to drive and use machines:** Reboxetine is not sedative per se. However, as with all psychoactive drugs, caution patients about operating machinery and driving. **Undesirable effects:** Adverse events occurring more frequently than placebo are: dry mouth, constipation, insomnia, paraesthesia, increased sweating

required. **Package and NHS Price:** Pack of 60 tablets in blisters £19.80. **Legal Category:** POM **Marketing Authorisation Holder:** Pharmacia & Upjohn Limited, Davy Avenue, Milton Keynes, MK5 8PH, UK. **Marketing Authorisation Number:** PL 0032/0216. **Date of Preparation:** October 1997. **References:** 1. Montgomery SA. *Journal of Psychopharmacology* 1997 (in press). 2. Dubini A. et al. *European Neuropsychopharmacol.* 1997; 7 (Suppl 1): S57-S70. 3. Bosc M. et al. *European Neuropsychopharmacol.* 1997; 7 (Suppl 1): S57-S70. Further information is available from Pharmacia & Upjohn Limited, Davy Avenue, Knowlhill, Milton



Because  
community  
re-integration  
is not that  
simple.

**ABBREVIATED PRESCRIBING INFORMATION:**

**Presentation:** Coated tablets containing 5mg, 7.5mg or 10mg of olanzapine. The tablets also contain lactose.  
**Uses:** Schizophrenia, both as initial therapy and for maintenance of response. **Further Information:** In studies of patients with schizophrenia and associated depressive symptoms, mood score improved significantly more with olanzapine than with haloperidol. **Pharmacodynamics:** Olanzapine was associated with significantly greater improvements in both negative and positive schizophrenic symptoms than placebo or comparator in most studies.

**Dosage and Administration:** 10mg/day orally, as a single dose without regard to meals. Dosage may subsequently be adjusted within the range of 5-20mg daily. An increase to a dose greater than the routine therapeutic dose of 10mg/day is recommended only after clinical assessment. **Children:** Not recommended under 18 years of age. **The elderly:** A lower starting dose (5mg/day) is not routinely indicated but should be considered when clinical factors warrant. **Hepatic and/or renal impairment:** A lower starting dose (5mg) may be considered. When more than one factor is present which might result in slower metabolism (female gender, elderly age, non-smoking status), consideration should be given to decreasing the starting dose. Dose escalation should be conservative in such patients. **Contra-indications:** Known hypersensitivity to any ingredient of the product. Known risk for narrow-angle glaucoma.

**Warnings and Special Precautions:** Caution in patients with prostatic hypertrophy, or paralytic ileus and related conditions. Caution in patients with elevated ALT and/or AST, signs and symptoms of hepatic impairment, pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic drugs. As with other neuroleptic drugs, caution in patients with low leucocyte and/or neutrophil counts for any reason, a history of drug-induced bone marrow depression/toxicity, bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hypereosinophilic conditions or with myeloproliferative disease. Thirty-two patients with clozapine-related neutropenia or agranulocytosis histories received olanzapine without decreases in baseline neutrophil counts. Although, in clinical trials, there were no reported cases of NMS in patients receiving olanzapine, if such an event occurs, or if there is unexplained high fever, all antipsychotic drugs, including olanzapine, must be discontinued. Caution in patients who have a history of seizures or have conditions associated with seizures. If signs or symptoms of tardive dyskinesia appear, a dose reduction or drug discontinuation should be considered. Caution when taken in combination with other centrally acting drugs and alcohol. Olanzapine may enhance the effects of direct and

**Antipsychotic Efficacy for First-line Use**



**Making Community Re-integration the Goal**

elderly. However, blood pressure should be measured periodically in patients over 65 years, as with other antipsychotics. As with other antipsychotics, caution when prescribed with drugs known to increase QTc interval, especially in the elderly. In clinical trials, olanzapine was not associated with a persistent increase in absolute QT intervals. **Interactions:** Metabolism may be induced by concomitant smoking or carbamazepine therapy. **Pregnancy and Lactation:**

Olanzapine had no teratogenic effects in animals. Because human experience is limited, olanzapine should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus. Olanzapine was excreted in the milk of treated rats but it is not known if it is excreted in human milk. Patients should be advised not to breast feed an infant if they are taking olanzapine. **Driving, etc:** Because olanzapine may cause somnolence, patients should be cautioned about operating hazardous machinery, including motor vehicles. **Undesirable Effects:** The only frequent (>10%) undesirable effects associated with the use of olanzapine in clinical trials were somnolence and weight gain. Occasional undesirable effects included dizziness, increased appetite, peripheral oedema, orthostatic hypotension, and mild, transient anticholinergic effects, including constipation and dry mouth. Transient, asymptomatic elevations of hepatic transaminases, ALT, AST have been seen occasionally. Olanzapine-treated patients had a lower incidence of parkinsonism, akathisia and dystonia in trials compared with titrated doses of haloperidol. Photosensitivity reaction or high creatinine phosphokinase were reported rarely. Plasma prolactin levels were sometimes elevated, but associated clinical manifestations were rare. Asymptomatic haematological variations were occasionally seen in trials. **For further information see summary of product characteristics.** **Legal Category:** POM. **Marketing Authorisation Numbers:** EU/1/96/022/004 EU/1/96/022/006 EU/1/96/022/008 EU/1/96/022/009 EU/1/96/022/010. **Basic NHS Cost:** £52.73 per pack of 28 x 5mg tablets. £105.47 per pack of 28 x 10mg tablets. £158.20 perpack of 56 x 7.5mg tablets. £210.93 per pack of 56 x 10mg tablets. **Date of Preparation or Last Review:** April 1997. **Full Prescribing Information is Available From:** Eli Lilly and Company Limited, Dextra Court, Chapel Hill, Basingstoke, Hampshire RG21 5SY. Telephone: Basingstoke (01256) 315000.

<https://doi.org/10.1192/bpl.1997.11.0002008> Published online by Cambridge University Press



# PRESCRIPTION FOR DEPRESSION




Illustration © Janet Atkinson/SIS Paris

Tender loving care and

**SEROXAT**  
PAROXETINE

'Seroxat' helps get depressed patients back to normal, liberating them from everyday stresses and anxiety.

For all those depressed patients who need a helping hand to face life again, make 'Seroxat' your first-choice prescription for depression.

Rebuilding the lives  
of anxious depressed patients



### Prescribing information

**Presentation** 'Seroxat' Tablets, PL 10592/0001-2, each containing either 20 or 30 mg paroxetine as the hydrochloride. 30 (OP) 20 mg tablets, £20.77; 30 (OP) 30 mg tablets, £31.16. 'Seroxat' Liquid, PL 10592/0092, containing 20 mg paroxetine as the hydrochloride per 10 ml. 150 ml (OP), £20.77. **Indications** Treatment of symptoms of depressive illness of all types including depression accompanied by anxiety. Treatment of symptoms of obsessive compulsive disorder (OCD). Treatment of symptoms and prevention of relapse of panic disorder with or without agoraphobia. **Dosage Adults:** *Depression:* 20 mg a day. Review response within two to three weeks and if necessary increase dose in 10 mg increments to a maximum of 50 mg according to response. *Obsessive compulsive disorder:* 40 mg a day. Patients should be given 20 mg a day initially and the dose increased weekly in 10 mg increments. Some patients may benefit from a maximum dose of 60 mg a day. *Panic disorder:* 40 mg a day. Patients should be given 10 mg a day initially and the dose increased weekly in 10 mg increments. Some patients may benefit from a maximum dose of 50 mg a day. Give orally once a day in the morning with food. The tablets should not be chewed. Continue treatment for a sufficient period, which may be several months for depression or longer for OCD and panic disorder. As with many psychoactive medications abrupt discontinuation should be avoided – see **Adverse reactions.** *Elderly:* Dosing should commence at the adult starting dose and may be increased in weekly 10 mg increments up to a maximum of 40 mg a day according to response. *Children:* Not recommended. *Severe renal impairment (creatinine clearance <30 ml/min) or severe hepatic impairment:* 20 mg a day. Restrict incremental dosage if required to lower end of range. **Contra-indication** Hypersensitivity to paroxetine. **Precautions** History of mania. Cardiac conditions: caution. Caution in patients with epilepsy; stop treatment if seizures develop. Driving and operating machinery. **Drug interactions** Do not use with or within two weeks after MAO inhibitors; leave a two-week gap before starting MAO inhibitor treatment. Possibility of interaction with tryptophan. Great caution with warfarin and other oral anticoagulants. Use lower doses if given with drug metabolising enzyme inhibitors; adjust dosage if necessary with drug metabolising enzyme inducers. Alcohol is not advised. Use lithium with caution and monitor lithium levels. Increased adverse effects with phenytoin; similar possibility with other anticonvulsants. **Pregnancy and lactation** Use only if potential benefit outweighs possible risk. **Adverse reactions** In controlled trials most commonly nausea, somnolence, sweating, tremor, asthenia, dry mouth, insomnia, sexual dysfunction (including impotence and ejaculation disorders), dizziness, constipation and decreased appetite. Also spontaneous reports of dizziness, vomiting, diarrhoea, restlessness, hallucinations, hypomania, rash including urticaria with pruritus or angioedema, and symptoms suggestive of postural hypotension. Extrapyramidal reactions reported infrequently; usually reversible abnormalities of liver function tests and hyponatraemia described rarely. Symptoms including dizziness, sensory disturbance, anxiety, sleep disturbances, agitation, tremor, nausea, sweating and confusion have been reported following abrupt discontinuation of 'Seroxat'. It is recommended that when antidepressant treatment is no longer required, gradual discontinuation by dose-tapering or alternate day dosing be considered. **Overdosage** Margin of safety from available data is wide. Symptoms include nausea, vomiting, tremor, dilated pupils, dry mouth, irritability, sweating and somnolence. No specific antidote. General treatment as for overdose with any antidepressant. Early use of activated charcoal suggested. **Legal category** POM. 3.3.97

**SB** **SmithKline Beecham**  
Pharmaceuticals

Welwyn Garden City, Hertfordshire AL7 1EY 'Seroxat' is a registered trade mark.

© 1997 SmithKline Beecham Pharmaceuticals

## Books from Gaskell

# The Psychotherapy of Psychosis

Edited by Chris Mace and Frank Margison

This book provides an unusually comprehensive survey of the current state and prospects of psychological methods of treatment for people with schizophrenia and other psychotic illnesses. It will be an invaluable resource for mental health professionals and clinical managers involved in their care, and essential reading for psychiatrists at all levels of experience.

The three traditions of psychotherapy and integrated approaches are covered. Recent research in the process and outcome of psychotherapy is reviewed and summarised. Clear advice is also given on treatment techniques and settings with reference to national policies.

As with other titles in the series, there is frequent use of boxes, tables and figures to set out important points and key information.

1997, 296pp, ISBN 1 901242 04 8, £25.00

Gaskell books are available from the Publications Department, Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG (Tel. +44(0)171 235 2351, extension 146).

The latest information on College publications is available on the INTERNET at:  
<http://www.demon.co.uk/rcpsych/>





# Seminars in General Adult Psychiatry

**NEW!**

Edited by George Stein & Greg Wilkinson

A major new textbook of adult general psychiatry by leading experts in the field and the centrepiece of the Seminars series. This multi-authored textbook places its greatest emphasis on detailed clinical descriptions of the common psychiatric disorders and their place within the ICD-10 and DSM-IV schemes. Psychological and biological treatments are covered in depth giving the reader an insight into the issues involved in modern patient care. Although primarily intended for doctors preparing for their MRCPsych, the text provides a comprehensive well-referenced review of the whole of modern clinical psychiatry and will be of use to consultant psychiatrists and other health professionals in the mental health field. As with other titles in the series, frequent use of boxes, tables and figures is made to set out important points and key information. The book is presented in two volumes as a boxed set.

• £55.00 • Vol 1: 810pp Vol 2: 698pp • Published January 1998 • ISBN 0 902241 91 5

## CONTENTS

**Volume 1** Foreword • Preface • Clinical features of depressive disorders • Mania, bipolar disorder and treatment • The causes of depression • Drug treatment of depression • Electroconvulsive therapy and other treatments • Psychological treatment of depression • Schizophrenia – the clinical picture • The aetiology of schizophrenia • The psychological and social management of schizophrenia • Schizoaffective, paranoid and other psychoses • Suicide and deliberate self-harm • Anxiety disorders • Phobic disorders • Obsessive-compulsive disorder • Hysteria • Hypochondriasis and other somatoform disorders • Index

**Volume 2** Foreword • Preface • Personality disorders • Treatment and outcome of the personality disorders • Anorexia nervosa and bulimia nervosa • Postpartum and related disorders • Organic psychiatric disorders • Psychiatric aspects of neurological disorders • Toxic, metabolic and endocrine disorders • Sleep disorders • Diagnosis, classification and measurement • Mental health services • Psychiatry in general practice • Index

## How to order

The books in this series and other College publications are available from good bookshops and from Book Sales, Publications Department, Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG. Credit card orders can taken over the telephone (+44(0)171 235 2351, extension 146). The latest information on Gaskell publications is available on the College website at: [www.rcpsych.ac.uk](http://www.rcpsych.ac.uk)

## Other titles in the series

### **Seminars in the Psychiatry of Learning Disabilities**

Edited by Oliver Russell

£15.00, 282pp, 1997, ISBN 0 901242 02 1

### **Seminars in Psychiatric Genetics**

By P. McGuffin, M.J. Owen, M.C. O'Donovan, A. Thapar & I.I. Gottesman

£10.00, 240pp, 1994, ISBN 0 902241 65 6

### **Seminars in Alcohol and Drug Misuse**

Edited by Jonathan Chick & Roch Cantwell

£13.50, 246pp, 1994, ISBN 0 902241 70 2

### **Seminars in Practical Forensic Psychiatry**

Edited by Derek Chiswick & Rosemary Cope

£17.50, 359pp, 1995, ISBN 0 902241 78 8

### **Seminars in Clinical Psychopharmacology**

Edited by David J. King

£20.00, 544pp, 1995, ISBN 0 902241 73 7

### **Seminars in Liaison Psychiatry**

Edited by Elspeth Guthrie & Francis Creed

£15.00, 312pp, 1996, ISBN 0 902241 95 8

### **Seminars in Basic Neurosciences**

Edited by Gethin Morgan & Stuart Butler

£15.00, 336pp, 1993, ISBN 0 902241 61 3

### **Seminars in Psychology and the Social Sciences**

Edited by Digby Tantam & Max Birchwood

£17.50, 358pp, 1994, ISBN 0 902241 62 1

### **Seminars in Child and Adolescent Psychiatry**

Edited by Dora Black & David Cottrell

£15.00, 298pp, 1993, ISBN 0 902241 55 9

## Titles in preparation

### **Seminars in the Psychiatry for the Elderly**

Edited by Rob Butler & Brice Pitt

### **Seminars in Psychotherapy**

Edited by Sandra Grant & Jane Naismith

COLLEGE SEMINARS SERIES